European synthetic biology company Octarine raises $1.8M USD in...

Today, Octarine Bio ApS (“Octarine” or the “Company”), a synthetic biology company developing biosynthetic platforms for cannabinoids, psychedelics and their novel improved derivatives announced the...(PRWeb November 12, 2020)Read the full story at https://www.prweb.com/releases/european_synthetic_biology_company_octarine_raises_1_8m_usd_in_funding_and_enters_pre_clinical_studies_with_novel_improved_cannabinoid_and_psychedelic_derivatives/prweb17533542.htm
Source: PRWeb: Medical Pharmaceuticals - Category: Pharmaceuticals Source Type: news